Humanigen Inc (fka HGENQ)

[cowtown jay]

Regarding T cells becoming exhausted, that is an issue being addressed by Gracell with their FasTCAR platform. Gracell filed an F-3 Registration statement in this regard last month.

"Company Overview
We are a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies to address major industry challenges and fulfill unmet medical needs in the treatment of cancer. We aim to develop next-generation, transformational CAR-T cell therapies to broaden the use of this potent treatment modality across a wide range of disease indications in hematological malignancies, solid tumors and beyond.
Our pioneering platforms, FasTCAR and TruUCAR, are designed to provide significant advantages as highlighted below:
•
FasTCAR. With FasTCAR, we are able to deliver younger, less exhausted T cells for autologous cell therapies with enhanced activities and next-day manufacturing versus the industry norm of one to six weeks. FasTCAR is designed to address the most pressing challenges associated with autologous therapies, such as lengthy manufacturing time, suboptimal cell quality, high therapy cost and poor T cell fitness."

See Prospectus Summary, page 1.

https://www.sec.gov/Archives/edgar/data/1826492/000110465923094883/tm2324412-1_f3.htm

It's interesting to think that not only does lenz improve the efficacy of treatment therapeutics, but perhaps that extends to improving the efficacy of the treatment method.